McKesson Sells 20% Stake in Med-Surg Unit to Apollo for $7.4B

McKesson Corporation is cashing out $7.4 billion of equity in its medical supply distribution arm while keeping the keys to the operation. The healthcare giant announced Saturday it's selling a 20% stake in its Medical-Surgical Solutions division to funds managed by Apollo Global Management, in a transaction that values the business at $37 billion on an enterprise value basis — a multiple that reflects the steady cash generation of distributing gauze, syringes, and surgical instruments to America's physician offices and outpatient surgery centers.

The deal structure is textbook financial engineering: McKesson retains 80% ownership and complete operational control of the division, treating it as a consolidated subsidiary for accounting purposes. Apollo gets a slice of the distribution economics without operational headaches. McKesson gets a pile of cash it says will fund up to $6 billion in share buybacks, with the remainder earmarked for debt reduction and general corporate purposes.

What makes this worth more than a footnote in McKesson's capital allocation playbook is the valuation. The $37 billion enterprise value represents roughly 1.4x the division's trailing revenue — a premium that suggests Apollo sees durable margin expansion in a business that's less exposed to drug pricing volatility than McKesson's pharmaceutical distribution operations. Medical-Surgical Solutions generated $26.4 billion in revenue for fiscal 2025, making it the company's second-largest segment after U.S. Pharmaceutical distribution.

The transaction is expected to close in McKesson's fiscal fourth quarter ending March 31, 2027, subject to regulatory clearance and customary conditions. Goldman Sachs served as financial advisor to McKesson, with Wachtell, Lipton, Rosen & Katz providing legal counsel. Apollo was advised by Kirkland & Ellis.

Apollo's interest in Medical-Surgical Solutions tracks with the firm's broader healthcare infrastructure thesis — owning picks-and-shovels businesses that benefit from structural volume growth regardless of which political party controls drug pricing policy. The division serves more than 250,000 physician offices, surgery centers, and alternate care sites across North America. It's not sexy, but it's stable.

The business has tailwinds. Outpatient surgical volumes continue migrating from hospitals to ambulatory surgery centers, where cost structures are lower and scheduling is easier. An aging population means more procedures. And supply chain resiliency — a polite term for "not running out of gloves during the next pandemic" — has become a C-suite priority for healthcare providers willing to pay for reliability.

McKesson's scale matters here. The company operates one of the largest medical supply distribution networks in North America, with fulfillment infrastructure that took decades to build and would cost billions to replicate. Competitors include Cardinal Health, Owens & Minor, and Medline Industries, but McKesson's breadth — from pharmaceuticals to medical supplies to health IT — gives it cross-selling leverage that pure-play distributors lack.

For Apollo, this is a bet on operating leverage. The division's EBITDA margins have room to expand as McKesson consolidates distribution centers, automates fulfillment, and negotiates better terms with manufacturers. Private equity playbook 101: buy into a cash-generative business where incremental revenue drops to the bottom line at high rates, then harvest distributions while the operator does the work.

From McKesson's side, this is about capital efficiency. The company has been systematically simplifying its portfolio for years — exiting European operations, divesting its IT businesses, and focusing on North American pharmaceutical and medical distribution. Selling a minority stake in Med-Surg lets McKesson pull forward value without triggering the tax bill and operational disruption of a full sale.

Brian Tyler, McKesson's CEO, framed the deal as unlocking value while preserving strategic flexibility. "This transaction allows us to monetize a portion of our Medical-Surgical Solutions business at an attractive valuation while maintaining operational control," Tyler said in the announcement. The company plans to deploy up to $6 billion of the proceeds into share repurchases — a signal that management believes McKesson's stock is undervalued relative to the division's standalone worth.

The buyback math is straightforward. McKesson's shares have traded in a range this year, and the company has historically returned capital to shareholders through a combination of dividends and repurchases. A $6 billion buyback program would retire roughly 5-7% of shares outstanding at recent prices, providing immediate accretion to earnings per share and sending a message to the market that management sees upside.

The remainder of the proceeds — roughly $1.4 billion — will go toward debt reduction and general corporate uses, giving McKesson additional balance sheet flexibility for M&A or organic investment. The company hasn't been acquisition-hungry lately, but having dry powder available positions it to move opportunistically if attractive tuck-in targets emerge in medical distribution or oncology services.

Critically, McKesson retains 80% ownership and consolidates the division's financials. This isn't a joint venture with split governance. Apollo is a financial partner, not a strategic co-pilot. McKesson's management continues to run day-to-day operations, set capital allocation priorities within the division, and integrate Med-Surg with the company's broader healthcare distribution strategy. Apollo's board representation and governance rights weren't disclosed in the announcement, but standard minority stake agreements typically include protective provisions on major asset sales, significant debt issuance, and changes of control — not operational decision-making.

Apollo's move is part of a wider trend of private equity firms buying into healthcare infrastructure businesses that sit adjacent to, but insulated from, the most politically volatile parts of the sector. Drug pricing is a political football. Hospital reimbursement rates are perpetually squeezed. But distributing medical supplies to outpatient facilities? Boring, essential, and less likely to end up in a congressional hearing.

Similar transactions have played out across healthcare services. Blackstone took a stake in ambulatory surgery center operator Amsurg years ago. KKR and other PE firms have rolled up dental practices, veterinary clinics, and dermatology groups — businesses with recurring revenue, fragmented markets, and operational improvement opportunities. Medical supply distribution checks the same boxes: predictable demand, high barriers to entry, and margin expansion potential through scale and automation.

What's different here is the size. A $37 billion valuation puts Medical-Surgical Solutions in the same league as publicly traded healthcare distributors. For context, Cardinal Health's entire market cap hovers around $25-30 billion depending on the day. McKesson is monetizing a business segment that, on a standalone basis, would rank among the largest pure-play medical distributors in North America.

Apollo is betting it can drive value through operational improvements McKesson might not prioritize on its own — or at least that the market will eventually value the division's cash flows more richly in a private or semi-private structure. That's speculative, but it's the bet.

The deal also reflects private equity's appetite for minority stakes in corporate carve-outs. These structures let PE firms deploy large checks into high-quality assets without the complexity of a full buyout, while corporations get liquidity without losing strategic control. Expect more of this as CFOs look for creative ways to unlock value in divisions that are profitable but underappreciated by public market investors.

The transaction requires regulatory approval, though the announcement didn't flag any expected hurdles. Medical supply distribution isn't as scrutinized as pharmaceutical wholesaling, and a minority stake transaction typically draws less antitrust attention than a full acquisition. The FTC and DOJ will review the deal under Hart-Scott-Rodino requirements, but absent a competitive overlap between Apollo's existing portfolio companies and McKesson's Med-Surg operations, clearance should be procedural.

The expected close in McKesson's fiscal Q4 2027 — by March 31, 2027 — gives both sides nearly a year to navigate approvals, finalize agreements, and structure the governance framework. That timeline also lets McKesson lock in the buyback execution during fiscal 2027, smoothing the EPS impact across multiple quarters rather than creating a one-time pop.

The $37 billion enterprise value is the headline number, but it's worth unpacking what it implies about the division's profitability and growth trajectory. At $26.4 billion in trailing revenue, the valuation represents roughly 1.4x sales — a multiple that's typical for distribution businesses with mid-to-high single-digit EBITDA margins.

McKesson hasn't disclosed Med-Surg's standalone EBITDA, but peer distributors like Cardinal Health and Owens & Minor operate their medical segments at EBITDA margins in the 4-6% range. If Med-Surg is performing at the high end of that range, the division could be generating $1.5-1.8 billion in annual EBITDA, implying an EV/EBITDA multiple in the low-to-mid 20s — aggressive for a distribution business unless there's meaningful margin expansion baked into Apollo's underwriting.

That's where the operational improvement thesis comes in. Apollo likely sees a path to 100-200 basis points of margin expansion through procurement optimization, fulfillment automation, and SKU rationalization. If the division can push EBITDA margins from 5% to 7% over the next few years while growing revenue at a mid-single-digit clip, the returns start to look compelling — especially if Apollo structures its stake with preferential distribution rights.

The valuation also suggests confidence in the secular shift toward outpatient care. Ambulatory surgery centers are growing faster than hospital-based surgical volumes, and physician office visits are increasingly handling procedures that once required inpatient stays. Med-Surg's customer base sits at the center of that shift, which should provide a revenue tailwind independent of broader healthcare spending trends.

Large-scale minority investments in healthcare distribution aren't common, but the structure has precedent. In 2020, Blackstone acquired a majority stake in Amsurg (now Envision Physician Services' surgery center business) in a deal that valued the ASC platform at roughly $9.9 billion. That transaction was a full buyout, not a minority stake, but the valuation multiples were similar — mid-teens EV/EBITDA for a business levered to outpatient procedural volume growth.

More recently, PE firms have pursued minority stakes in corporate divisions where a full sale wasn't feasible or desirable. These deals give corporations liquidity while preserving operational integration and tax efficiency. McKesson's approach mirrors that playbook: get paid now, keep control, and let the PE partner share in upside without complicating the org chart.

Beyond the immediate capital return, this deal reshapes how McKesson is positioned in the public markets. The company has long traded at a discount to its intrinsic value, in part because investors struggle to parse the economics of its sprawling pharmaceutical and medical distribution operations. By putting a hard valuation on Med-Surg, McKesson is effectively telling the market: this division alone is worth $37 billion, and we're keeping 80% of it.

That should, in theory, force analysts to revisit their sum-of-the-parts models. If Med-Surg is worth $37 billion and McKesson retains $29.6 billion of that value, the company's pharmaceutical distribution, oncology services, and prescription technology businesses are being valued at whatever's left of the market cap after backing out Med-Surg. The math might reveal that the market has been undervaluing McKesson's non-Med-Surg operations — or overvaluing them. Either way, the transaction creates a reference point that didn't exist before.

There's also the question of what comes next. McKesson has been a serial portfolio optimizer, and this deal could be a proof of concept for similar transactions in other divisions. The company's oncology and specialty distribution businesses, for instance, operate in higher-margin niches where a financial partner might see similar value-creation opportunities. If the Apollo partnership goes smoothly, don't be surprised if McKesson explores comparable structures elsewhere in the portfolio.

For now, though, McKesson's message is clear: we're confident enough in Med-Surg's value to sell a piece of it at this price, and we're confident enough in our own stock to deploy $6 billion into buybacks. That's a double bet on valuation — one that the market will validate or punish over the next 12-18 months.

The deal also insulates McKesson from activist pressure. By proactively monetizing Med-Surg and returning capital, the company is checking the boxes that activists typically demand: unlock hidden value, simplify the structure, return cash to shareholders. Harder to argue McKesson is being complacent when it just signed a $7.4 billion check from Apollo and announced a massive buyback.

Strip away the press release language, and Apollo is buying exposure to a business that's effectively an annuity on America's outpatient healthcare infrastructure. Every surgery center needs gloves. Every physician office needs syringes. Every infusion clinic needs IV supplies. And McKesson's Medical-Surgical Solutions is one of the few distributors with the scale, logistics network, and customer relationships to serve all of them reliably.

The business doesn't rely on breakthrough innovation or hit products. It wins by being 1% better at forecasting demand, 2% more efficient in fulfillment, and 5% more reliable when supplies are tight. That's not exciting, but it compounds. And for Apollo, which manages capital that needs to generate mid-teens returns over 5-7 year horizons, a business with steady cash flow, margin expansion potential, and limited obsolescence risk is exactly the kind of asset that fits the mandate.

The downside case is that McKesson's scale advantages erode as manufacturers sell direct to large health systems or as Amazon and other tech-enabled entrants nibble at the market. But medical supply distribution has proven surprisingly resilient to disruption. Regulatory complexity, cold chain requirements, and the need for just-in-time delivery create moats that e-commerce platforms struggle to cross. Apollo is betting those moats hold.

The upside case is that Med-Surg becomes the cash cow that funds Apollo's returns while McKesson uses the division's growth to support its own capital allocation priorities. Both sides get what they want: Apollo gets distributions, McKesson gets validation of its portfolio's value, and the division keeps operating largely as it did before — just with a new line item on the cap table.

The announcement leaves several threads dangling. Apollo's governance rights weren't disclosed — does it get board seats, veto rights on major capex, or protective provisions on asset sales? The structure of the investment also wasn't detailed: is this preferred equity with a liquidation preference, common equity with tag-along rights, or something more exotic? Those terms will matter when it comes time for Apollo to exit, whether through a sale of its stake back to McKesson, a secondary transaction, or an eventual IPO of the division.

There's also the question of how this affects McKesson's M&A strategy. The company has been disciplined about acquisitions, preferring tuck-ins and bolt-ons to transformative deals. Does bringing Apollo into the Med-Surg structure change that calculus? If the division wants to acquire a regional competitor or expand into adjacent product categories, does Apollo have a say in those decisions, or does McKesson's 80% ownership give it unilateral authority?

And finally, what does this mean for McKesson's long-term portfolio strategy? The company has spent the last decade simplifying, divesting non-core assets, and focusing on North American distribution. Is this minority sale the endgame for Med-Surg, or is it a stepping stone toward an eventual full exit? McKesson's management hasn't signaled any intent to sell the division outright, but private equity partnerships have a way of evolving. If Apollo delivers strong returns and the market rewards the transaction, the path to a larger deal becomes easier to imagine.

For now, though, the deal stands as a clean example of financial engineering that works for both sides: McKesson gets liquidity without losing control, Apollo gets exposure to a cash-generative infrastructure business, and shareholders get a $6 billion buyback. Whether that value creation proves durable depends on execution — both in how McKesson deploys the proceeds and in how Apollo and McKesson collaborate to drive margin improvement in Med-Surg. The market will be watching. So will every other corporate treasurer sitting on undervalued divisions wondering if a similar playbook might work for them.